[Email This]

Vioxx Drug Safety Hearings

FDA, Merck and Vioxx:
Putting Patient Safety First?

Testimony Before the U.S. Senate Finance Committee

November 18, 2004

These files are in PDF format and can be viewed using Adobe Acrobat Reader.

• Sen. Charles Grassley (Rep. - Iowa)
  
• Sen. Max Baucus (Dem. - Montana)
  

• Dr. David J. Graham, MPH, Associate Director for Science, Office of Drug Safety, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC
  

• Dr. Gurkirpal Singh, Adjunct Clinical Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
  
  
• Dr. Bruce M. Psaty, PhD, Professor, Medicine & Epidemiology, University of Washington, Cardiovascular Health Research Unit, Seattle, WA
  
  

• Dr. Sandra L. Kweder, Acting Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC
  

• Mr. Raymond V. Gilmartin, Chairman, President & Chief Executive Officer, Merck & Co., Whitehouse Station, NJ